VCANBIO CELL & GENE ENGINEERING CORP., LTD

Vcanbio Cell & Gene Engineering Corp., Ltd

Equities

600645

CNE000000545

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
18.73 ^CNY	+0.21%		-5.78%	-7.60%

Apr. 25	Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 25	Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zhongyuan Union Stem Cell Bio-Engineering Corporation Appoints Wu Mingyuan as General Manager

February 10, 2014 at 02:48 am EST

At the 35th session of 7th directorate meeting held on February 7, 2014, Zhongyuan Union Stem Cell Bio-engineering Corporation discussed and approved the appointment of Wu Mingyuan as General Manager.

Latest news about Vcanbio Cell & Gene Engineering Corp., Ltd

Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	Apr. 19	CI
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million.	Apr. 17	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	Apr. 01	CI
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares.	Feb. 18	CI
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan	Feb. 16	CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has received CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	Dec. 25	CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	Nov. 07	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug	23-10-16	MT
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership).	23-09-28	CI
Vcanbio Cell & Gene Engineering Corp., Ltd(XSSC:600645) added to S&P Global BMI Index	23-09-18	CI
MET Group signs energy supply deal with Commonwealth LNG	23-09-04	RE
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Vcanbio Cell & Gene’s Pulmonary Fibrosis Treatment Wins Orphan Drug Designation in US	23-08-14	MT
Vcanbio Cell & Gene Unit Gets Nod to Begin Clinical Trial of Respiratory Distress Medication	23-06-08	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Vcanbio Cell & Gene Engineering Wins Nod to Trial Stem Cell Therapy For Liver Cirrhosis	23-02-13	MT
C-Mer Eye Care Raises HK$116.1 Million in Share Subscription Deal	22-12-08	MT
C-Mer Eye Care To Issue More Than 30 Million New Shares to Vcanbio Cell Chairman	22-12-04	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Energy firms MET and HH2E to invest in Baltic electrolysis plant	22-06-15	RE

Chart Vcanbio Cell & Gene Engineering Corp., Ltd

Duration

Period

Chart Vcanbio Cell & Gene Engineering Corp., Ltd

More charts

Company Profile

VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-19 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
VCANBIO CELL & GENE ENGINEERING CORP., LTD	-7.60%	1.2B
BIOMÉRIEUX	-4.17%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.76%	8.1B
DIASORIN S.P.A.	+8.70%	5.87B
LANTHEUS HOLDINGS, INC.	+28.39%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.28%	4.29B
10X GENOMICS, INC.	-52.84%	3.16B
ANDON HEALTH CO., LTD.	+12.93%	2.72B
VITROLIFE AB	-2.36%	2.37B
MYRIAD GENETICS, INC.	+28.84%	2.23B

Diagnostic & Testing Substances